KBI Biopharma and Selexis Hold Joint Ribbon Cutting of the Expanded State-of-the-Art Facility in Geneva, Switzerland
Read More
BIO Asia Taiwan, Taiwan, Asia | July 27 – 31, 2022
Bioprocessing summit, Boston, USA | August 15 – 18, 2022
BioProcess International Conference & Exhibition (BPI - Boston), Boston, USA | September 27 – 30, 2022
Nordic Life Science Partnering, Malmö, Sweden | September 28 – 29, 2022
BioJapan, Yokohama, Japan | October 12 – 14, 2022
BioEurope Fall, Leipzig, Germany | October 24 – 26, 2022
CPHI, Frankfurt, Germany |November 1 – 3, 2022
Festival of Biologics - European, Basel, Switzerland | November 2 – 4, 2022
PEGS Europe (Protein & Antibody Engineering Summit), Barcelona, Spain | November 14 – 16, 2022
BIOFIT, Strasbourg, France | November 29 – 30, 2022
Antibody Engineering & Theraputics (US), San Diego, USA | December 4 - 8, 2022
Explore the SUREtechnology Platform™
For more than 20 years, Selexis has been at the forefront of helping the biopharmaceutical industry advance life-saving mAb therapeutics into the clinic and to the market.
At Selexis, we believe in the promise of newer biologics and have committed significant resources to ensure our SUREtechnology Platform™ can meet the new expression challenges that these difficult-to-express proteins present.
We are proud of the role that Selexis’ cell line technology is playing in helping to deliver on the promise of bispecifics, which is a rapidly expanding class of drugs showing impressive results in multiple clinical trials.
Selexis SA, a JSR Life Sciences company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 160 drug products in clinical development and the manufacture of 10 commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
Copyright© 2022 Selexis SA. All Rights Reserved.